Abstract: The present invention relates to a hydroxamate compound represented by formula (I), a preparation method therefor, and an application thereof. The present invention also relates to a pharmaceutical composition comprising the compound as an active ingredient and a use of the compound or pharmaceutical composition for treating and/or preventing related diseases mediated by TYK2.

Abstract: A Gate Driver on Array (GOA) circuit and a display panel are provided. The GOA circuit includes a plurality of cascaded GOA units. An Nth stage GOA unit includes a pull-up control circuit, a pull-up output circuit and a scan direction control circuit. The scan direction control circuit can be controlled by the clock signal to realize the alternating forward and backward scanning. The output terminal of the scan direction control circuit is connected with the output terminal of the pull-up control circuit, and the output terminal potential of the pull-up control circuit can be alternately changed.

Abstract: The present embodiment provides a GOA circuit and a display panel, in which the GOA circuit comprises a forward/backward scanning control module, an output module, a potential regulation module, a node control module, and a voltage stabilizer module. A first node and a third node are not conducted when a second node is at a second potential; the first node and the third node are conducted and have a second potential when the second node is at a third potential, wherein the second potential is opposite to the third potential. Thus, GOA circuit's leakage issue existing in the TP suspension stage can be improved.

Abstract: An array substrate comprises a base substrate, a light-shielding layer disposed on the base substrate, and a plurality of transistors disposed in an array on a side of the light-shielding layer away from the base substrate. The light-shielding layer comprises a plurality of light-shielding portions. Orthographic projections of a source terminal of each of the transistors and a drain terminal of one adjacent transistor in a same row on the base substrate are located on one same light-shielding portion, and orthographic projections of a source terminal and a drain terminal of one same transistor on the base substrate are respectively located on two adjacent light-shielding portions that are spaced apart. A display panel comprises the array substrate.

Abstract: The present application provides a GOA circuit and a display panel. In the GOA circuit, one of two GOA units of a same stage in GOA sub circuits at left and right sides of the display panel is deployed only with an all-on module and the other one of the two GOA units is deployed only with an all-off module. In such a way, both the number of the all-on modules and the number of the all-off modules required in the GOA unit are halved, thereby reducing the area occupied by the GOA circuit. It is beneficial for realizing a display panel with a narrow bezel.

Abstract: A display panel and a display device are provided. The display panel and display device include gate driver on array (GOA) units in a first column, GOA units in a second column, and signal input lines. By adjusting a positional relationship between the signal input line and the GOA units in the first column and the GOA unit in the second column, the GOA units in the first column and the GOA units in the second column may share the signal input line, so as to save a set of signal input lines and reduce a width of the frame area.

Abstract: The present application discloses a display panel and a display device. The display panel includes a non-display region and a gate driver on array (GOA) unit region in the non-display region. The GOA unit region includes multilevel GOA units arranged in multiple columns, thereby improving a space limitation problem associated with arranging a plurality of GOA units in a display panel while the display panel achieves high resolution.

Abstract: A display panel and a display device are provided. The display panel and display device include gate driver on array (GOA) units in a first column, GOA units in a second column, and signal input lines. By adjusting a positional relationship between the signal input line and the GOA units in the first column and the GOA unit in the second column, the GOA units in the first column and the GOA units in the second column may share the signal input line, so as to save a set of signal input lines and reduce a width of the frame area.

Abstract: The present application provides a GOA circuit and a display panel. In the GOA circuit, one of two GOA units of a same stage in GOA sub circuits at left and right sides of the display panel is deployed only with an all-on module and the other one of the two GOA units is deployed only with an all-off module. In such a way, both the number of the all-on modules and the number of the all-off modules required in the GOA unit are halved, thereby reducing the area occupied by the GOA circuit. It is beneficial for realizing a display panel with a narrow bezel.

Abstract: The present invention relates to a new method of producing functionally active recombinant porcine Intrinsic Factor as well as the protein (i.e., porcine Intrinsic Factor) produced thereby. In particular, the vector comprising the DNA encoding the protein is introduced into a Chinese Hamster Ovary (CHO) host cell under conditions sufficient for optimal expression of functional protein. The expressed protein may then be subjected to three methods ultimately resulting in a protein having at least 97% purity.

Abstract: The present invention relates to a new method of producing functionally active recombinant porcine Intrinsic Factor as well as the protein (i.e., porcine Intrinsic Factor) produced thereby. In particular, the vector comprising the DNA encoding the protein is introduced into a Chinese Hamster Ovary (CHO) host cell under conditions sufficient for optimal expression of functional protein. The expressed protein may then be subjected to three methods ultimately resulting in a protein having at least 97% purity.

Abstract: Methods and kits for measurement of concentration of FK778 in a biological sample by means of an immunoassay, preferably a competitive immunoassay. In one aspect, the method and kit involve the use of (a) an antibody to FK778 conjugated to a label, e.g., an acridinium label, (b) an antibody to FK778 not conjugated to a label, (c) a solid phase containing an antibody to a first hapten, e.g., a fluorescein hapten, and (d) a bihapten comprising a first hapten and FK778 or an analogue of FK778, e.g., a bihapten comprising a fluorescein hapten and a FK778 hapten. In another aspect, the method and kit involve the use of (a) antibody to FK778, (b) a bihapten comprising FK778 or an analogue of FK778 and a first hapten, e.g., a bihapten comprising the fluorescein hapten and the hapten of FK778 or an analogue of FK778, and (c) a pretreatment reagent.

Abstract: Methods and kits for measurement of concentration of FK778 in a biological sample by means of an immunoassay, preferably a competitive immunoassay. In one aspect, the method and kit involve the use of (a) an antibody to FK778 conjugated to a label, e.g., an acridinium label, (b) an antibody to FK778 not conjugated to a label, (c) a solid phase containing an antibody to a first hapten, e.g., a fluorescein hapten, and (d) a bihapten comprising a first hapten and FK778 or an analogue of FK778, e.g., a bihapten comprising a fluorescein hapten and a FK778 hapten. In another aspect, the method and kit involve the use of (a) antibody to FK778, (b) a bihapten comprising FK778 or an analogue of FK778 and a first hapten, e.g., a bihapten comprising the fluorescein hapten and the hapten of FK778 or an analogue of FK778, and (c) a pretreatment reagent.

Abstract: Methods and kits for measurement of concentration of FK778 in a biological sample by means of an immunoassay, preferably a competitive immunoassay. In one aspect, the method and kit involve the use of (a) an antibody to FK778 conjugated to a label, e.g., an acridinium label, (b) an antibody to FK778 not conjugated to a label, (c) a solid phase containing an antibody to a first hapten, e.g., a fluorescein hapten, and (d) a bihapten comprising a first hapten and FK778 or an analogue of FK778, e.g., a bihapten comprising a fluorescein hapten and a FK778 hapten. In another aspect, the method and kit involve the use of (a) antibody to FK778, (b) a bihapten comprising FK778 or an analogue of FK778 and a first hapten, e.g., a bihapten comprising the fluorescein hapten and the hapten of FK778 or an analogue of FK778, and (c) a pretreatment reagent.

Abstract: Methods and kits for measurement of concentration of FK778 in a biological sample by means of an immunoassay, preferably a competitive immunoassay. In one aspect, the method and kit involve the use of (a) an antibody to FK778 conjugated to a label, e.g., an acridinium label, (b) an antibody to FK778 not conjugated to a label, (c) a solid phase containing an antibody to a first hapten, e.g., a fluorescein hapten, and (d) a bihapten comprising a first hapten and FK778 or an analogue of FK778, e.g., a bihapten comprising a fluorescein hapten and a FK778 hapten. In another aspect, the method and kit involve the use of (a) antibody to FK778, (b) a bihapten comprising FK778 or an analogue of FK778 and a first hapten, e.g., a bihapten comprising the fluorescein hapten and the hapten of FK778 or an analogue of FK778, and (c) a pretreatment reagent.